- Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome
-
Park JH, Song JS, Choi ST
- KMID: 2378089
- J Rheum Dis.
- 2017 Apr;24(2):108-113.
- doi: 10.4078/jrd.2017.24.2.108
The main treatment for Antiphospholipid syndrome (APS) is long-term anticoagulation with an oral vitamin K antagonist, although these are associated with numerous problems. Rivaroxaban is a direct anti-factor Xa inhibitor,... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Hematologic Changes between Rivaroxaban and Aspirin for Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty
-
Song MH, Kim BH, Ahn SJ, Yoo SH, Kim YJ
- KMID: 2185303
- J Korean Orthop Assoc.
- 2012 Dec;47(6):410-415.
- doi: 10.4055/jkoa.2012.47.6.410
PURPOSE: To compare the hematologic changes and the rates of transfusion of patients using rivaroxaban or aspirin for venous thromboembolism prophylaxis after a total knee arthroplasty. MATERIALS AND METHODS: Among patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Multiple Intracranial Hemorrhage Following Intravenous Recombinant Plasminogen Activator in the Patients Taking Rivaroxaban
-
Ryu JC, Kwon JH, Choi SH, Kim WJ
- KMID: 2370972
- J Korean Neurol Assoc.
- 2017 Feb;35(1):50-52.
- doi: 10.17340/jkna.2017.1.13
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Acute Spinal Subdural Hematoma in a Patient Taking Rivaroxaban
-
Bang WS, Kim KT, Park MK, Sung JK, Lee H, Cho DC
- KMID: 2401702
- J Korean Med Sci.
- 2018 Jan;33(5):e40.
- doi: 10.3346/jkms.2018.33.e40
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Hemorrhagic pericarditis associated with rivaroxaban in an atrial fibrillation patient with pacemaker
-
Rhew SH, Kim SS
- KMID: 2390933
- Transl Clin Pharmacol.
- 2017 Sep;25(3):138-140.
- doi: 10.12793/tcp.2017.25.3.138
Rivaroxaban is a new oral anticoagulant used for the prevention of stroke in patients with atrial fibrillation. Hemorrhagic pericarditis is known to occur with rivaroxaban; however, only a few case... -
- CITED
-
- Close
- SHARE
-
- Close
- Epidural hematoma after total knee arthroplasty in a patient receiving rivaroxaban: A case report
-
Shin S, Kang H, Lee JW, Kim HG, Choi ES
- KMID: 2434207
- Anesth Pain Med.
- 2019 Jan;14(1):102-105.
- doi: 10.17085/apm.2019.14.1.102
Rivaroxaban, a factor Xa inhibitor, is one of the newly developed direct oral anticoagulants (DOAC). In recent times, it has been increasingly used in the prevention of pulmonary embolism in... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
-
Kim HJ, Koo SM, Ham NS, Kim KU, Uh ST, Kim YK
- KMID: 2320494
- Tuberc Respir Dis.
- 2014 Mar;76(3):127-130.
The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is... -
- CITED
-
- Close
- SHARE
-
- Close
- Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis
-
Jeong HK, Lee KH, Park HW, Yoon NS, Kim MC, Lee N, Kim JS, Ahn Y, Jeong MH, Park JC, Cho JG
- KMID: 2432256
- Chonnam Med J.
- 2019 Jan;55(1):54-61.
- doi: 10.4068/cmj.2019.55.1.54
Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation (AF). However, there has been concern for the risk of major... -
- CITED
-
- Close
- SHARE
-
- Close
- Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
-
Yang H, Kim SR, Song MJ
- KMID: 2373155
- Clin Mol Hepatol.
- 2016 Dec;22(4):499-502.
- doi: 10.3350/cmh.2016.0016
Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Delayed bleeding after implant surgery in patients taking novel oral anticoagulants: a case report
-
Kim C, Dam C, Jeong J, Kwak EJ, Park W
- KMID: 2384477
- J Dent Anesth Pain Med.
- 2017 Jun;17(2):143-147.
- doi: 10.17245/jdapm.2017.17.2.143
The use of novel oral anticoagulants (NOACs) has increased in recent times in an effort to overcome the shortcomings of warfarin. They are being used primarily for the prevention of... -
- CITED
-
- Close
- SHARE
-
- Close
- Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
-
Lee JH, Oh YM, Lee SD, Lee JS
- KMID: 2456269
- J Korean Med Sci.
- 2019 Jun;34(21):e160.
- doi: 10.3346/jkms.2019.34.e160
BACKGROUND: Low-molecular-weight heparin (LMWH) is the standard treatment for venous thromboembolism (VTE) in patients with active cancer. However, use of factor Xa inhibitors, such as rivaroxaban, is increasing on the... -
- CITED
-
- Close
- SHARE
-
- Close
- Practice Preferences on Dabigatran and Rivaroxaban for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation
-
Park YK, Kang JE, Kim SJ, La HO, Rhie SJ
- KMID: 2358236
- Korean J Clin Pharm.
- 2016 Sep;26(3):207-212.
- doi: 10.0000/kjcp.2016.26.3.207
OBJECTIVE: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in... -
- CITED
-
- Close
- SHARE
-
- Close
- A Study on the Efficacy and Safety of Rivaroxaban in Urologic Cancer-Associated Venous Thromboembolism
-
Lee JH, You D, Lee SD, Oh YM, Lee JS
- KMID: 2470403
- Korean J Urol Oncol.
- 2019 Dec;17(3):178-185.
- doi: 10.22465/kjuo.2019.17.3.178
PURPOSE: Although direct oral anticoagulants (DOACs) are recommended as an alternative to low-molecular weighted heparin for cancer-associated venous thromboembolism (VTE), there is no firm evidence on the efficacy and safety... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
-
Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C
- KMID: 2438536
- Korean Circ J.
- 2019 Mar;49(3):252-263.
- doi: 10.4070/kcj.2018.0220
BACKGROUND AND OBJECTIVES: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial... -
- CITED
-
- Close
- SHARE
-
- Close
- Guidance for Endoscopic Procedures in Patients Taking Novel Oral Anticoagulants
-
Kim KO
- KMID: 2383557
- Korean J Helicobacter Up Gastrointest Res.
- 2016 Dec;16(4):185-188.
- doi: 10.7704/kjhugr.2016.16.4.185
Anticoagulant agents are used to reduce the risk of thromboembolic complications in patients with atrial fibrillation or deep vein thrombosis. Several new generation of oral anticoagulants have been approved. These... -
- CITED
-
- Close
- SHARE
-
- Close
- Thrombotic Occlusion of an Inferior Vena Cava Filter during Maintenance with a Novel Anticoagulant
-
Park DH, Kim MD, Lee SH
- KMID: 2218775
- Korean J Med.
- 2016 Jun;90(6):524-527.
- doi: 10.3904/kjm.2016.90.6.524
A 68-year-old woman presented with chest pain and dyspnea and was diagnosed with a massive pulmonary embolism. Bleeding colon cancer was detected incidentally during anticoagulation therapy. After stabilization, she underwent... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparisons of Bleeding Risks between Rivaroxaban and Dalteparin for Treatment of Venous Thromboembolism in Cancer Patients
-
Kim YK, An SH, Kim JY, Chung JE, Gwak HS
- KMID: 2358234
- Korean J Clin Pharm.
- 2016 Sep;26(3):195-200.
- doi: 10.0000/kjcp.2016.26.3.195
BACKGROUND: Venous thromboembolism (VTE) is a common and life-threating condition in cancer patients. Low molecular weight heparins (LMWH), such as dalteparin, are recommended in the treatment of VTE. Also, rivaroxaban,... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
-
Patel MR, Peacock WF, Tamayo S, Sicignano , Hopf KP, Yuan Z
- KMID: 2409818
- Clin Exp Emerg Med.
- 2018 Mar;5(1):43-50.
- doi: 10.15441/ceem.17.216
OBJECTIVE: Patients with nonvalvular atrial fibrillation (AF) and renal disease (RD) who receive anticoagulation therapy appear to be at greater risk of major bleeding (MB) than AF patients without RD.... -
- CITED
-
- Close
- SHARE
-
- Close
- Rivaroxaban and Acetylsalicylic Acid for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty in Korean Patients
-
Chung KS, Shin TY, Park SH, Kim H, Choi CH
- KMID: 2420351
- Knee Surg Relat Res.
- 2018 Sep;30(3):247-254.
- doi: 10.5792/ksrr.17.092
PURPOSE: To investigate the incidence of venous thromboembolism (VTE) after total knee arthroplasty (TKA) with chemoprophylaxis using acetylsalicylic acid (AA) or rivaroxaban in Korean patients. MATERIALS AND METHODS: Between May 2011... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of NOAC in Cardioversion
-
Kim JB
- KMID: 2308908
- Int J Arrhythm.
- 2016 Mar;17(1):46-50.
- doi: 10.18501/arrhythmia.2016.007
Cardioversion increases the risk for stroke or systemic embolic events, and patients scheduled for cardioversions need several weeks of anticoagulant treatment to prevent these adverse events. Anticoagulant therapy should be... -
- CITED
-
- Close
- SHARE
-
- Close
